Elsevier

Biochemical Pharmacology

Volume 35, Issue 10, 15 May 1986, Pages 1743-1751
Biochemical Pharmacology

Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta

https://doi.org/10.1016/0006-2952(86)90333-3Get rights and content

Abstract

Cyclic nucleotide phosphodiesterase (PDE) activity from the 105,000 g supernatant of human, bovine and rat aorta smooth muscle cells was resolved by DEAE-trisacryl chromatography into three major forms showing similar properties in each species. In addition to the two PDE forms previously characterized in vascular tissues (a cAMP-PDE and a calmodulin-dependent PDE), a cGMP-PDE, insensitive to calmodulin, was isolated and characterized in the aorta of the three species. Each isolated PDE form was differently inhibited by various chemical compounds, and these compounds produced effects on cyclic nucleotide levels in isolated rat aorta which could be expected from their inhibitory effect on isolated PDE forms. At concentrations non-selectively inhibiting the three isolated PDE forms (including the calmodulin-dependent one), IBMX (3-isobutyl-I-methylxanthine) and trequinsin markedly and dose-dependently increased both cAMP and cGMP aorta levels (up to 7-fold, in presence of 500 μM IBMX). By contrast selective inhibitors of cGMP-PDE or cAMP-PDE could only induce a moderate elevation (by 1.5–3-fold) in cGMP or cAMP levels, respectively. In the case of M&B 22,948, a highly specific and potent inhibitor of cGMP-PDE, a concentration-dependent increase in tissue cGMP levels was produced by concentrations (in the μM range) active in inhibiting the isolated enzyme. In the case of selective cAMP-PDE inhibitors (rolipram and Ro 20-1724), however, a significant increase in aorta cAMP content was induced only in the presence of drug concentrations which were much higher (200 and 500 μm, respectively) than those inhibiting the isolated enzyme (IC50:5 and 18 μM, respectively). Inhibitors of both cGMP-PDE and eAMP-PDE (dipyridamole, cilostamide and its derivative AAL 05) produced the same moderate effects as did the combination of a selective cGMP-PDE inhibitor and a selective cAMP-PDE inhibitor on the levels of both cGMP and cAMP. These results show that the three forms of PDE isolated from aortic smooth muscle retain properties that they exhibit in the tissue and which are similar in the three species examined, including man. They suggest that each form participates in a specific manner to the regulation of cAMP and cGMP concentrations in aorta smooth muscle cells.

References (40)

  • J.N. Wells et al.

    Biochim. hiophvs. Ada

    (1975)
  • T.M. Keravis et al.

    Biochim. biophys. Acta

    (1980)
  • B. Ilien et al.

    Biochem. biophys. Res. Commun.

    (1978)
  • M. Hagiwara et al.

    Biochem. Pharmac.

    (1984)
  • C. Lugnier et al.

    Biochem. biophys. Res. Commun.

    (1983)
  • D. Ruppert et al.

    Life Sci

    (1982)
  • W.Y. Cheung

    J. biol. Chem.

    (1971)
  • T. Isobe et al.

    Biochim. biophys. Acta

    (1977)
  • P. Schoeffter et al.

    Eur. J. Pharmac.

    (1982)
  • H.L. Cailla et al.

    Analyt. Biochem.

    (1973)
  • H.L. Cailla et al.

    Analyt. Biochem.

    (1976)
  • J.M. Kissane et al.

    J. biol. Chem.

    (1958)
  • F. Setaro et al.

    Analyt. Biochem.

    (1976)
  • M.C. Mumby et al.

    J. biol. Chem.

    (1982)
  • T. Yamamoto et al.

    J. biol. Chem.

    (1983)
  • F. Demésy-Waeldele et al.

    Eur. J. Pharmac.

    (1977)
  • P. Schoeffter et al.

    Eur. J. Pharmac.

    (1985)
  • M.M. Appleman et al.
  • M.M. Appleman et al.
  • J.A. Beavo et al.

    Mol. cell. Endocrinol.

    (1982)
  • Cited by (264)

    • PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking

      2021, Biochemical Pharmacology
      Citation Excerpt :

      Thus, among the eleven-known PDE families, the PDE4 family, hydrolyzes specifically the cyclic 3′, 5′-AMP (cAMP) in 5′-AMP and H+. PDE4 was characterized by its specific inhibitor rolipram [36], and was designed as a COPD therapeutic target. This family is pointed out by its great number of subfamilies (A, B, C and D), by its great number of variants (>25 human variants), being distributed in various tissues and subcellular compartments, allowing a fine tuning of compartmentalized intracellular signaling [7].

    • Ion channels as effectors of cyclic nucleotide pathways: Functional relevance for arterial tone regulation

      2020, Pharmacology and Therapeutics
      Citation Excerpt :

      Binding of a specific region in the N-terminus of the R subunits to A-kinase anchoring proteins (AKAPs) targets PKA activity to specific subcellular membranes and multiprotein complexes (Ercu & Klussmann, 2018). Of note, the concentration of cAMP in vascular tissues is usually ≈ 5 times higher than cGMP (Lugnier, Schoeffter, Le Bec, Strouthou, & Stoclet, 1986) although relative levels can show great variability. Intracellular levels of cAMP and cGMP are mitigated by the activity of PDEs, a large group of enzymes which in mammals is composed of 11 families that encompass 21 genes and multiple variants (see reviews by (Bobin et al., 2016; Keravis & Lugnier, 2012; Maurice et al., 2014)).

    • Design and synthesis of 3-aminophthalazine derivatives and structural analogues as PDE5 inhibitors: anti-allodynic effect against neuropathic pain in a mouse model

      2019, European Journal of Medicinal Chemistry
      Citation Excerpt :

      PDE1, PDE3, PDE4 and PDE5 were isolated by anion exchange chromatography from bovine aortic smooth muscle cytosolic fraction according to the literature [3]. PDE2 was isolated from human platelets following the methods indicated in the literature [2,3]. Purified PDEs were stored until use at −80 °C in small aliquots (200 μL).

    View all citing articles on Scopus
    View full text